Why the study?
Does a polymer-free umirolimus-coated stent improve safety and efficacy compared to a bare-metal stent in patients at high bleeding risk undergoing PCI?
Does a polymer-free umirolimus-coated stent improve safety and efficacy compared to a bare-metal stent in patients at high bleeding risk undergoing PCI?
In patients at high bleeding risk undergoing PCI, a polymer-free umirolimus-coated stent with 1-month DAPT is superior to a bare-metal stent for both safety and efficacy.
Supports polymer-free umirolimus-coated stents for high-bleeding-risk PCI; extends randomized evidence beyond bare-metal stents for shorter DAPT.
Among patients at high risk for bleeding who underwent PCI, a polymer-free umirolimus-coated stent was superior to a bare-metal stent with respect to the primary safety and efficacy end points when used with a 1-month course of dual antiplatelet therapy. (Funded by Biosensors Europe; LEADERS FREE ClinicalTrials.gov number, NCT01623180.).
No takes yet. Share an insight, caveat, or question.
Urban et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: